FLGT:NSD-Fulgent Genetics Inc. (USD)

EQUITY | Diagnostics & Research | NASDAQ Global Market

Last Closing

USD 20.35

Change

-0.23 (-1.12)%

Market Cap

USD 0.17B

Volume

0.31M

Analyst Target

USD 16.33
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Fulgent Genetics Inc is a technology company offering genetic testing to provide physicians with clinically actionable diagnostic information used to improve the overall quality of patient care.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-30 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

+3.25 (+0.73%)

USD 37.69B
ICLR ICON PLC

-4.51 (-1.94%)

USD 23.48B
ILMN Illumina Inc

+1.66 (+1.14%)

USD 22.77B
NTRA Natera Inc

+1.99 (+1.60%)

USD 14.84B
EXAS EXACT Sciences Corporation

+0.82 (+1.18%)

USD 12.84B
MEDP Medpace Holdings Inc

-11.41 (-3.46%)

USD 10.15B
RDNT RadNet Inc

-0.94 (-1.39%)

USD 4.95B
SHC Sotera Health Co

-0.09 (-0.57%)

USD 4.39B
NEOG Neogen Corporation

+0.23 (+1.60%)

USD 2.98B
GH Guardant Health Inc

+1.28 (+5.87%)

USD 2.52B

ETFs Containing FLGT

LDUK:LSE L&G Quality Equity Divide.. 4.98 % 0.00 %

-0.30 (0.00%)

USD 0.04B
UKDV:LSE SPDR S&P UK Dividend Aris.. 4.78 % 0.00 %

-0.01 (0.00%)

USD 0.14B
SPYG:XETRA SPDR S&P UK Dividend Aris.. 4.78 % 0.00 %

-0.07 (0.00%)

USD 0.11B
UKDV:SW SPDR® S&P UK Dividend Ar.. 4.78 % 0.00 %

N/A

USD 0.14B
IUKD:SW iShares UK Dividend UCITS.. 4.74 % 0.00 %

-0.03 (0.00%)

USD 0.84B
IUKD:LSE iShares UK Dividend UCITS 4.72 % 0.00 %

-0.70 (0.00%)

USD 0.84B
EXH5:XETRA iShares STOXX Europe 600 .. 2.60 % 0.00 %

-0.34 (0.00%)

USD 0.30B
SXIPEX:SW iShares STOXX Europe 600 .. 2.60 % 0.00 %

N/A

USD 0.09B
FDD First Trust STOXX® Europ.. 0.00 % 0.57 %

-0.04 (0.00%)

N/A
XASX:LSE Xtrackers - Xtrackers MSC.. 0.00 % 0.00 %

-2.40 (0.00%)

N/A
EXH5:F iShares STOXX Europe 600 .. 0.00 % 0.00 %

N/A

N/A
EXSH:F iShares STOXX Europe Sele.. 0.00 % 0.00 %

-0.15 (0.00%)

N/A
IQQD:F iShares UK Dividend UCITS 0.00 % 0.00 %

-0.05 (0.00%)

N/A
ISPA:F iShares (DE) I - iShares .. 0.00 % 0.00 %

-0.38 (0.00%)

N/A
SPYG:F SSgA SPDR ETFs Europe I P.. 0.00 % 0.00 %

-0.09 (0.00%)

N/A
EXSH:XETRA iShares STOXX Europe Sele.. 0.00 % 0.00 %

-0.14 (0.00%)

USD 0.35B
IQQD:XETRA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -29.61% 34% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.61% 34% F 19% F
Trailing 12 Months  
Capital Gain -30.00% 50% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.00% 50% F 27% F
Trailing 5 Years  
Capital Gain 194.93% 87% B+ 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 194.93% 87% B+ 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 105.76% 93% A 95% A
Dividend Return 105.76% 93% A 95% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 217.43% 13% F 7% C-
Risk Adjusted Return 48.64% 86% B+ 80% B-
Market Capitalization 0.17B 67% D+ 66% D+

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 7.49 79% 78%
Price/Book Ratio 0.55 85% 88%
Price / Cash Flow Ratio 22.26 14% 12%
Price/Free Cash Flow Ratio -4.34 67% 76%
Management Effectiveness  
Return on Equity -14.58% 71% 48%
Return on Invested Capital -6.28% 82% 43%
Return on Assets -3.47% 80% 43%
Debt to Equity Ratio 0.26% 85% 86%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector